282 related articles for article (PubMed ID: 16278402)
1. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.
van Erp NP; Baker SD; Zhao M; Rudek MA; Guchelaar HJ; Nortier JW; Sparreboom A; Gelderblom H
Clin Cancer Res; 2005 Nov; 11(21):7800-6. PubMed ID: 16278402
[TBL] [Abstract][Full Text] [Related]
2. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
[TBL] [Abstract][Full Text] [Related]
3. Modulation of irinotecan metabolism by ketoconazole.
Kehrer DF; Mathijssen RH; Verweij J; de Bruijn P; Sparreboom A
J Clin Oncol; 2002 Jul; 20(14):3122-9. PubMed ID: 12118026
[TBL] [Abstract][Full Text] [Related]
4. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
Yokokawa A; Kaneko S; Endo S; Minowa Y; Ayukawa H; Hirano R; Nagashima F; Naruge D; Okano N; Kobayashi T; Kawai K; Furuse J; Furuta T; Shibasaki H
Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):317-324. PubMed ID: 33619631
[TBL] [Abstract][Full Text] [Related]
5. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.
Crews KR; Stewart CF; Jones-Wallace D; Thompson SJ; Houghton PJ; Heideman RL; Fouladi M; Bowers DC; Chintagumpala MM; Gajjar A
Clin Cancer Res; 2002 Jul; 8(7):2202-9. PubMed ID: 12114421
[TBL] [Abstract][Full Text] [Related]
6. Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.
van der Bol JM; Loos WJ; de Jong FA; van Meerten E; Konings IR; Lam MH; de Bruijn P; Wiemer EA; Verweij J; Mathijssen RH
Eur J Cancer; 2011 Apr; 47(6):831-8. PubMed ID: 21216137
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics of irinotecan.
Chabot GG
Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
[TBL] [Abstract][Full Text] [Related]
8. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy.
Gajjar A; Chintagumpala MM; Bowers DC; Jones-Wallace D; Stewart CF; Crews KR
Cancer; 2003 May; 97(9 Suppl):2374-80. PubMed ID: 12712459
[TBL] [Abstract][Full Text] [Related]
9. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
[TBL] [Abstract][Full Text] [Related]
10. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.
van der Bol JM; Mathijssen RH; Creemers GJ; Planting AS; Loos WJ; Wiemer EA; Friberg LE; Verweij J; Sparreboom A; de Jong FA
Clin Cancer Res; 2010 Jan; 16(2):736-42. PubMed ID: 20068078
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
Santos A; Zanetta S; Cresteil T; Deroussent A; Pein F; Raymond E; Vernillet L; Risse ML; Boige V; Gouyette A; Vassal G
Clin Cancer Res; 2000 May; 6(5):2012-20. PubMed ID: 10815927
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of irinotecan.
Toffoli G; Cecchin E; Corona G; Boiocchi M
Curr Med Chem Anticancer Agents; 2003 May; 3(3):225-37. PubMed ID: 12769780
[TBL] [Abstract][Full Text] [Related]
13. Determination of drug interactions occurring with the metabolic pathways of irinotecan.
Charasson V; Haaz MC; Robert J
Drug Metab Dispos; 2002 Jun; 30(6):731-3. PubMed ID: 12019202
[TBL] [Abstract][Full Text] [Related]
14. Effects of green tea compounds on irinotecan metabolism.
Mirkov S; Komoroski BJ; RamÃrez J; Graber AY; Ratain MJ; Strom SC; Innocenti F
Drug Metab Dispos; 2007 Feb; 35(2):228-33. PubMed ID: 17108060
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of UGT1A1*1 and UGT1A1*6 catalyzed glucuronidation of SN-38 by silybins.
Li W; Chen YN; Chen YY; Wang Z; Wang Z; Jiang LL; Shi HC; Liu Y
Chem Biol Interact; 2022 Dec; 368():110248. PubMed ID: 36343684
[TBL] [Abstract][Full Text] [Related]
16. The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity.
Kawaguchi-Suzuki M; Frye RF; Zhu HJ; Brinda BJ; Chavin KD; Bernstein HJ; Markowitz JS
Drug Metab Dispos; 2014 Oct; 42(10):1611-6. PubMed ID: 25028567
[TBL] [Abstract][Full Text] [Related]
17. Influence of phenytoin on the disposition of irinotecan: a case report.
Murry DJ; Cherrick I; Salama V; Berg S; Bernstein M; Kuttesch N; Blaney SM
J Pediatr Hematol Oncol; 2002 Feb; 24(2):130-3. PubMed ID: 11990699
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.
Thompson PA; Gupta M; Rosner GL; Yu A; Barrett J; Bomgaars L; Bernstein ML; Blaney SM; Mondick J
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1027-37. PubMed ID: 18278496
[TBL] [Abstract][Full Text] [Related]
19. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
[TBL] [Abstract][Full Text] [Related]
20. Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease.
d'Esposito F; Nebot N; Edwards RJ; Murray M
Br J Clin Pharmacol; 2010 Sep; 70(3):400-8. PubMed ID: 20716241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]